NT-proBNP Predicted Outcome in Patients With Diabetes, CKD, Anemia

Major Finding: In an analysis adjusted for other predictive variables, TREAT participants in the highest tertile for both CRP and UPCR had a 20% annual rate of the composite cardiovascular end point of cardiovascular death, MI, stroke, or hospitalization for heart failure or myocardial ischemia.

Data Source: A secondary, post hoc analysis of data from TREAT, an international, double-blind, randomized, placebo-controlled, phase III study involving 4,038 patients with the triad at 623 centers.

Disclosures: TREAT was sponsored by Amgen. Dr. McMurray disclosed having received research funding and consulting fees from the company.